Delta 9 Cannabis Inc. Stocks

CA$ 0Last Updated 23.03.2026

Issuer Rating

2/7
Performance

Modest

Risk

High

Recommendation

Sell

Market Cap

CA$ 1.10M

Buy
Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
CA$ 0
Key Takeaways

Risk factor

Very high price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Very low or no dividends

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Delta 9 Cannabis Inc. operates as an integrated cannabis company. The company, through its subsidiary, Delta 9 Bio-Tech Inc., engages in the cultivation, processing, extraction, wholesale distribution, retail, and sale of medical and recreational cannabis products. Its products include dried cannabis flowers, pre-rolls, decontamination pods, and dried sift cannabis, as well as oils, and extracted and derivative products. The company also offers grow pods and live plants to other licensed and pre-licensed companies. In addition, it operates as a medical clinic that provides physician consultation services to patients seeking a medical recommendation for a cannabis prescription. As of April 20, 2022, the company owned and operated 35 retail stores under the Delta 9 brand name across the Canadian Prairies. Delta 9 Cannabis Inc. was incorporated in 2001 and is headquartered in Winnipeg, Canada.

Company Valuation

Fairly valued
4/7

From both historical and forecast perspectives, the stock is fairly priced compared to similar stocks. In particular, the stock is reasonably priced on P/E, of fair value

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis
X-channel

Buy

Sell

0 more stocks